Ultragenyx Pharmaceutical Inc.·4

Sep 29, 2:15 PM ET

Crombez Eric 4

4 · Ultragenyx Pharmaceutical Inc. · Filed Sep 29, 2023

Insider Transaction Report

Form 4
Period: 2023-09-27
Crombez Eric
EVP and Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-09-27+2,3512,351 total
    Exercise: $67.37Exp: 2027-03-01Common Stock (2,351 underlying)
Holdings
  • Common Stock

    30,512
Footnotes (2)
  • [F1]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
  • [F2]On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On September 27, 2023, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 784 shares on that date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION